Physician profile
John Morse
NPI 1497758445
$4,585.04
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $795 · 2021: $1,111 · 2022: $803 · 2023: $921 · 2024: $86.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,031.16 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $587.51 | 2019-2024 | Mounjaro |
| Pfizer INC. | $570.84 | 2019-2023 | |
| Amgen INC. | $380.12 | 2019-2023 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $289.38 | 2019-2024 | Breztri, Farxiga |
| Abbvie INC. | $250.57 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $245.51 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.29 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $129.14 | 2022-2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $98.96 | 2021 | |
| Exact Sciences Corporation | $91.36 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $87.76 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $74.54 | 2023 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $72.35 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $46.25 | 2021 | |
| Nevro Corp. | $45.20 | 2023-2024 | Senza |
| Biohaven Pharmaceutical Holding Company Ltd. | $44.36 | 2022 | |
| Allergan, INC. | $26.56 | 2019-2020 | |
| Dexcom, INC. | $24.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.33 | 2019 | |
| Shire North American Group INC | $22.67 | 2019 | |
| Daiichi Sankyo INC. | $22.37 | 2019 | |
| Antares Pharma, INC. | $20.33 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $20.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.11 | 2023 | |
| Shield Therapeutics INC | $18.20 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $16.87 | 2019 | |
| Corium, LLC | $16.74 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $15.67 | 2023 | Quviviq |
| Eisai INC. | $14.84 | 2021 | |
| Lundbeck LLC | $13.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.